Log in

Investors Buy Large Volume of Call Options on Marinus Pharmaceuticals (NASDAQ:MRNS)

Last updated on Wednesday, November 25, 2020 | 2020 MarketBeat

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) saw unusually large options trading on Tuesday. Investors acquired 2,746 call options on the company. This is an increase of approximately 2,029% compared to the average daily volume of 129 call options.

A number of large investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new position in Marinus Pharmaceuticals during the third quarter worth about $330,000. Point72 Asset Management L.P. acquired a new position in shares of Marinus Pharmaceuticals in the 3rd quarter worth approximately $964,000. Squarepoint Ops LLC bought a new position in shares of Marinus Pharmaceuticals during the 3rd quarter worth approximately $160,000. Trexquant Investment LP acquired a new stake in Marinus Pharmaceuticals in the 3rd quarter valued at $314,000. Finally, First Trust Advisors LP acquired a new stake in Marinus Pharmaceuticals in the 3rd quarter valued at $913,000. 74.45% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have weighed in on MRNS shares. Cantor Fitzgerald boosted their price target on Marinus Pharmaceuticals from $8.00 to $27.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 10th. Truist started coverage on Marinus Pharmaceuticals in a research report on Wednesday, September 30th. They issued a "buy" rating and a $35.00 price target for the company. BidaskClub raised Marinus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, September 17th. HC Wainwright boosted their price target on Marinus Pharmaceuticals from $9.00 to $35.00 and gave the stock a "buy" rating in a research report on Monday, September 28th. Finally, JMP Securities lifted their price objective on Marinus Pharmaceuticals from $7.00 to $26.00 and gave the stock an "outperform" rating in a research note on Friday, September 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company's stock. Marinus Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $27.22.

Shares of MRNS stock opened at $14.58 on Wednesday. Marinus Pharmaceuticals has a 12 month low of $4.16 and a 12 month high of $16.30. The company has a market capitalization of $446.06 million, a P/E ratio of -3.65 and a beta of 1.78. The stock has a 50 day moving average of $14.25 and a two-hundred day moving average of $10.59.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.09. On average, equities analysts expect that Marinus Pharmaceuticals will post -2.66 EPS for the current year.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Article: What are no-load funds?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


20 Stocks Analysts Can't Stop Upgrading

As you know, a single upgrade from a broker probably won't be a major game-changer for any single stock. But, what if there was a stock that had been upgraded by more than 10 different brokers during the last 90 days?

If ten different brokers have all upgraded a stock within the last few months and the price hasn't skyrocketed (at least, not yet), you would want to take a pretty hard look at it.

It turns out that there are actually 20 different companies that have been upgraded or had their price target increased at least ten times during the last ninety days by more than 10 different brokers. This slideshow lists those companies.

View the "20 Stocks Analysts Can't Stop Upgrading".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.